Drug intelligence / Profile preview

erfonrilimab (Alphamab Oncology)

Development stage: Unknown
Lead developer: AlphaMab Oncology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Erfonrilimab** is an investigational recombinant humanized PD-L1/CTLA-4 bispecific monoclonal antibody developed by Alphamab Oncology. It simultaneously blocks PD-L1-mediated PD-1 checkpoint signaling and CTLA-4-mediated inhibitory signaling, with the aim of restoring antitumor T-cell activity in the tumor microenvironment. The agent has been evaluated as monotherapy and in combination with chemotherapy for solid tumors, including pancreatic cancer and non-small cell lung cancer.

Other names: PD-L1/CTLA4 BsAb

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on erfonrilimab (Alphamab Oncology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erfonrilimab (Alphamab Oncology).

Explore the full profile